<DOC>
	<DOCNO>NCT02451852</DOCNO>
	<brief_summary>To provide access AZD9291 adult patient advanced/metastatic , epidermal growth factor receptor T790M mutation-positive non-small cell lung cancer .</brief_summary>
	<brief_title>AZD9291 US Expanded Access Program</brief_title>
	<detailed_description>- This multi-center , AZD9291 expand access protocol treatment adult patient advanced/metastatic EGFR T790M mutation-positive non-small cell lung cancer ( NSCLC ) receive prior EGFR TKI therapy least one additional line therapy ( â‰¥ 3rd line ) . Local test accepted confirmation T790 mutation status . Eligible patient enrol receive AZD9291 ( 80mg orally , daily ) long access program remain open continue show clinical benefit , judge treat physician</detailed_description>
	<mesh_term>Osimertinib</mesh_term>
	<criteria>Provision sign date , write informed consent prior treatment protocolspecific procedure Patients age least 18 year Locally advance metastatic EGFRm NSCLC , amenable curative surgery radiotherapy confirmation presence T790M mutation Two line prior therapy include least one EGFR TKI World Health Organization ( WHO ) performance status 02 . Females childbearing potential must use adequate contraceptive measure , breastfeed negative pregnancy test prior start dose . Males patient willing use barrier contraception . Previous treatment AZD9291 Patients currently receive ( unable stop use least 1 week prior receive first dose AZD9291 ) treatment know potent inhibitor inducer CYP3A4 Any evidence severe uncontrolled systemic disease , include uncontrolled hypertension , active bleeding diatheses , significantly impair bone marrow reserve organ function , include hepatic renal impairment , clinician 's opinion would significantly alter risk/benefit balance , active infection include hepatitis B , hepatitis C human immunodeficiency virus ( HIV ) . Patients symptomatic CNS metastasis neurologically unstable Past medical history ILD , druginduced ILD , radiation pneumonitis require steroid treatment , evidence clinically active ILD Any follow cardiac criterion : 1 . Mean resting correct QT interval ( QTc use Fredericia 's formula ) &gt; 470 msec 2 . Any clinically important abnormality rhythm , conduction morphology rest ECG ( e.g. , complete leave bundle branch block , third degree heart block , second degree heart block ) 3 . Any factor increase risk QTc prolongation risk arrhythmic event heart failure , hypokalemia , congenital long QT syndrome , family history long QT syndrome unexplained sudden death 40 year age first degree relative concomitant medication know prolong QT interval Any unresolved toxicity prior therapy Common Terminology Criteria Adverse Events ( CTCAE ) &gt; grade 3 time start treatment access program History hypersensitivity AZD9291 ( drug similar chemical structure class AZD9291 ) excipients agent Males female reproductive potential use effective method birth control females pregnant breastfeed positive ( urine serum ) pregnancy test prior access program entry</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>130 Years</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>